Warberg Asset Management’s Bone Biologics BBLG Stock Holding History

Warberg Asset Management’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-563	Closed	-$38.3K	–	250
2023 Q2	$38.3K	Buy	563 +542	+2,581%	+$142K	0.01%	139
2023 Q1	$7.75K	Hold	21	–	–	﹤0.01%	200
2022 Q4	$6.29K	Buy	+21	New	+$11.8K	﹤0.01%	222

Other funds holding BBLG

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Warberg Asset Management's BBLG Position: Q3 2023 in Review

Warberg Asset Management sold out of Bone Biologics (BBLG) in Q3 2023, closing a stake of 563 shares — an estimated $38.3K sold.

Warberg Asset Management first reported a position in BBLG in Q4 2022 and held it in 3 quarters. The position peaked at $38.3K in Q2 2023. 7 funds tracked by Wall St. Rank hold BBLG as of Q3 2023.

Warberg Asset Management reported no remaining Bone Biologics position as of Q3 2023 after selling out during the quarter.
Warberg Asset Management sold 563 Bone Biologics shares in Q3 2023, an estimated $38.3K.
Warberg Asset Management first reported a position in Bone Biologics in Q4 2022 and held it in 3 quarters.
Warberg Asset Management's Bone Biologics position peaked at $38.3K in Q2 2023.
7 funds tracked by Wall St. Rank held Bone Biologics as of Q3 2023.

Based on Warberg Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.